Oncoscience

Volume 2: Issue 2

pp71-204

Issue 2

About the Cover

The cover for the issue of Oncoscience features Figure 2 (“SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma”) from Blanco et al.

News

Check’-ing DLBCL

https://doi.org/10.18632/oncoscience.124

Itziar  Salaverria, Sílvia  Beà

p 71-72

PDF

Editorials

Functional polymorphisms in cancer

https://doi.org/10.18632/oncoscience.129

Divyansh  Agarwal, Christos  Hatzis, Lajos  Pusztai

p 73-74

PDF

TIC10/ONC201: a bend in the road to clinical development

https://doi.org/10.18632/oncoscience.133

Yoshimi Endo Greer, Stanley  Lipkowitz

p 75-76

PDF

BCC or not: Sufu keeps it in check

https://doi.org/10.18632/oncoscience.134

Wen-Chi  Yin, Zhu Juan Li, Chi-chung  Hui

p 77-78

PDF

Fighting Neuroblastomas with NBAT1

https://doi.org/10.18632/oncoscience.126

Gaurav Kumar Pandey, Chandrasekhar  Kanduri

p 79-80

PDF

Reviews

Genomics of chromophobe renal cell carcinoma: implications from a rare tumor for pan-cancer studies

https://doi.org/10.18632/oncoscience.130

Kimryn W. Rathmell, Fengju  Chen, Chad J. Creighton

p 81-90

Abstract |  PDF |  Full Text

Research Perspectives

Two preclinical tests to evaluate anticancer activity and to help validate drug candidates for clinical trials

https://doi.org/10.18632/oncoscience.132

Miguel  López-Lázaro

p 91-98

PDF |  Full Text

MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments

https://doi.org/10.18632/oncoscience.135

Mariska  Miranda, Esdy  Rozali, Kum Kum  Khanna, Fares  Al-Ejeh

p 99-101

PDF |  Full Text

SapC-DOPS nanovesicles: a novel targeted agent for the imaging and treatment of glioblastoma

https://doi.org/10.18632/oncoscience.122

Víctor M. Blanco, Richard  Curry, Xiaoyang  Qi

p 102-110

PDF |  Full Text

Research Papers

Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis – molecular insights from an iTRAQ™ quantitative proteomics study

https://doi.org/10.18632/oncoscience.120

Karthik  Narasimhan, Yew Mun Lee, Teck Kwang Lim, Sarah Alexra Port, Jin-Hua  Han, Chien-Shing  Chen, Qingsong  Lin

p 111-124

Abstract |  PDF |  Full Text |  Supplementary Materials |  Supplementary Table

RAS mutations vary between lesions in synchronous primary Colorectal Cancer: Testing only one lesion is not sufficient to guide anti-EGFR treatment decisions.

https://doi.org/10.18632/oncoscience.118

Mariana Petaccia de Macedo, Fernanda Machado de Melo, Júlia da Silva Silva Ribeiro, Celso Abdon Lopes de Mello, Maria Dirlei Ferreira de Souza Begnami, Fernando Augusto Soares, Dirce Maria Carraro, Isabela Werneck da Cunha

p 125-130

Abstract |  PDF |  Full Text

Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival

https://doi.org/10.18632/oncoscience.119

Esther  Martinez-Martinez, Irene  Gomez, Paloma  Martin, Antonio  Sanchez, Laura  Roman, Eva  Tejerina, Felix  Bonilla, Antonio  Garcia-Merino, Antonio Garcia de Herreros, Mariano  Provencio, Jose M. García

p 131-141

Abstract |  PDF |  Full Text

TR4 nuclear receptor enhances prostate cancer initiation via altering the stem cell population and EMT signals in the PPARG-deleted prostate cells

https://doi.org/10.18632/oncoscience.121

Shin-Jen  Lin, Dong-Rong  Yang, Nancy  Wang, Ming  Jiang, Hiroshi  Miyamoto, Gonghui  Li, Chawnshang  Chang

p 142-150

Abstract |  PDF |  Full Text |  Supplementary Materials

Analysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma

https://doi.org/10.18632/oncoscience.128

Edward  Sanders, Svenja  Diehl

p 151-186

Abstract |  PDF |  Full Text |  Supplementary Materials |  Supplementary Table

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations

https://doi.org/10.18632/oncoscience.131

Jorge Galvez Silva, Ferno F. Corrales-Medina, Ossama M. Maher, Nizar  Tannir, Winston W. Huh, Michael E Rytting, Vivek  Subbiah

p 187-192

Abstract |  PDF |  Full Text

Versican is a potential therapeutic target in docetaxel-resistant prostate cancer

https://doi.org/10.18632/oncoscience.136

Naoko  Arichi, Yozo  Mitsui, Miho  Hiraki, Shigenobu  Nakamura, Takeo  Hiraoka, Masahiro  Sumura, Hiroshi  Hirata, Yuichiro  Tanaka, Rajvir  Dahiya, Hiroaki  Yasumoto, Hiroaki  Shiina

p 193-204

Abstract |  PDF |  Full Text |  Supplementary Materials